Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HSPB1 | P04792 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL749155 | 0.89 | CRHBP (0.53) | CRHBPCRHR2MEN1KMT2AALDH1A1 | |
| SCHEMBL11714259 | 0.83 | HSPB1 (0.47) | CRHBPCRHR2MEN1PKMKMT2A | |
| SCHEMBL3083218 | 0.81 | MAPT (0.55) | CRHBPCRHR2MEN1KMT2AALDH1A1 | |
| SCHEMBL12055674 | 0.78 | CRHBP (0.50) | CRHBPCRHR2MEN1KMT2AALDH1A1 | |
| SCHEMBL3085696 | 0.76 | HPGD (0.46) | CRHBPCRHR2MEN1PKMKMT2A | |
| SCHEMBL17037126 | 0.75 | CRHBP (0.47) | CRHBPCRHR2MEN1KMT2AALDH1A1 | |
| SCHEMBL30166127 | 0.75 | APP (0.53) | CRHBPCRHR2MEN1KMT2AALDH1A1 | |
| SCHEMBL11118149 | 0.74 | SMN1; SMN2 (0.50) | CRHBPCRHR2ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL1565345 | 0.73 | TDP1 (0.47) | CRHBPCRHR2MEN1PKMKMT2A | |
| SCHEMBL2436528 | 0.73 | ALDH1A1 (0.49) | CRHBPCRHR2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070963-A1 | Compositions and methods for promoting neural regeneration | Neuberger, Timothy | 2008-03-20 | — | — | US | disclosed |
| US-7271187-B2 | Compositions and methods for promoting tissue regeneration | Neuberger, Tim (US) | 2007-09-18 | — | — | US | disclosed |
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | URI HERZBERG | 2002-05-09 | — | — | US | disclosed |
| WO-2001076592-A1 | COMPOSITIONS AND METHODS FOR PROMOTING NEURAL REGENERATION | ACORDA THERAPEUTICS, INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| US-4965284-A | IMMUNOMODULATORS | AMERICAN CYANAMID COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0342433-A2 | Substituted dibenzothiaphenes | AMERICAN CYANAMID COMPANY (US) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | TST, DCX, GAP43 | CRHBP 4066/4885CRHR2 4515/4885MEN1 4760/4885 |
| US-20080070963-A1 | Compositions and methods for promoting neural regeneration | GAP43, DCX, BDNF | CRHBP 4148/4885CRHR2 4492/4885MEN1 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.